<DOC>
	<DOC>NCT01376804</DOC>
	<brief_summary>This open-label, single arm study will evaluate the tolerability and efficacy of Valcyte (valganciclovir) in the prevention of cytomegalovirus disease in pediatric renal transplant recipients. After transplantation, patients (aged 4 months to 16 years) will receive Valcyte orally daily for up to 200 days post-transplant and will be followed for 52 weeks post-transplantation.</brief_summary>
	<brief_title>A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>Children, 4 months to 16 years of age Patient has received a kidney transplant At risk of developing cytomegalovirus disease Adequate hematological and renal function Able to tolerate oral medication Negative pregnancy test for females of childbearing potential Allergic or significant adverse reaction to acyclovir, valacyclovir or ganciclovir in the past Severe uncontrolled diarrhea (more than 5 watery stools per day) Liver enzyme elevation of more than five times the upper limit of normal for aspartate aminotransferase [AST (SGOT)] or alanine aminotransferase [ALT (SGPT)] Patient requires use of any protocol prohibited concomitant medication Previous participation in this clinical study</criteria>
	<gender>All</gender>
	<minimum_age>4 Months</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>